NIFTY 50 Market News

Sun Pharmaceutical Industries Share Price Live Updates: Announcement under Regulation 30 (LODR)-Credit Rating

Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full — India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.

Sun Pharma Share Price Live Updates: Sun Pharma's Monthly Return Overview

Sun Pharma Shares In Focus As Motilal Oswal Remains Bullish After Q1 Results — Check Hiked Target Price — Sun Pharma remains on track to expand its innovative medicine portfolio through enhanced marketing efforts on new launches, increasing the prescriber base the prescription rate for existing products, adds the brokerage.

Sun Pharma Share Price Live Updates: Sun Pharma dips below its 20-day Exponential Moving Average

MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline — Sun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.

Contamination Scare: Sun Pharma Recalls 10 Eye Drop Brands As Experts Warn Of Health Risks — Sun Pharma has recalled multiple eye drop brands in India over contamination concerns. The move has increased focus on pharmaceutical safety standards, with experts warning that unsafe eye drops can cause infections and potential vision damage.

Sun Pharma Share Price Live Updates: Sun Pharma's Recent Market Activity

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5% — Sun Pharma Q1 Results: Revenue from operations rose 10.5% YoY to Rs 15,300 crore during the reporting period.

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5% — Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore. The company highlighted semaglutide approvals and said the Organon acquisition remains on track for early 2027.

Sun Pharma Share Price Live Updates: Sun Pharma's Market Movement

Sun Pharma Share Price Live Updates: Sun Pharma's Market Performance Snapshot

Sun Pharma Share Price Live Updates: Sun Pharma's Price Movement Analysis

Sun Pharma Share Price Live Updates: Sun Pharma Reaches Impressive 52-Week High

NDTV Profit Business Leadership Awards: Sun Pharma's Dilip Sanghvi Wins 'Icon Of The Year' Award — Under Dilip Sanghvi's leadership, Sun Pharma expanded through organic growth and acquisitions.